Advertisement

Topics

Alliar Annouces 2Q17 Results

16:35 EDT 9 Aug 2017 | PR Newswire

BELO HORIZONTE, Brazil, Aug. 9, 2017 /PRNewswire/ -- Centro de Imagem Diagnósticos S.A. ("Alliar" or "Company") (B3: AALR3), announces today its results for the second quarter of 2017 (2Q17).

Highlights:

  • Net revenue1 growth of 20% YTD and 13% in Q2; same store sales of 13% e 11%;
  • Adjusted EBITDA of R$ 108.8 million YTD (+16%) and R$ 59.2 million in Q2 (+13%);
  • LTM EBITDA of R$ 218.8 million (R$ 227.5 million when annualizing acquisitions);
  • Net income growth of 224% YTD, reaching R$ 13.5 million and loss reversal in Q2, with a profit of R$ 4.7 million (+R$ 10.3 million vs 2Q16);
  • Net income after minority interests of R$ 9.7 million YTD and R$ 4.0 million in Q2 (vs. net loss of R$ 1.8 million and R$ 9.3 million in 2016);
  • Operating cash flow of R$ 72.6 million YTD (+2,105 bps) and 85% in Q2 (+3,057 bps);
  • Cash conversion of 67% YTD (+2,105 bps) and 85% in Q2 (+3,057 bps);
  • ROIC without goodwill of 15.8%;
  • Net promoter score (NPS) of 75.0%, 448 bps improvement vs. Q1;
  • Anticipation of the 2017/2018 organic expansion plan, with the opening of 2 new mega stores, totaling 4 openings in 2017.

(1) Excludes "construction revenue", accounting entry referring to the investment made at RBD (PPP Bahia).

For Further Information: ir.alliar.com   

CONTACT

INVESTOR RELATIONS TEAM Carlos Araujo | IRO
Francisco de Paula | IR Manager
Tel.: +5511 4369-1387
E-mail: ri@alliar.com

View original content:http://www.prnewswire.com/news-releases/alliar-annouces-2q17-results-300502428.html

SOURCE Alliar

NEXT ARTICLE

More From BioPortfolio on "Alliar Annouces 2Q17 Results"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...